Cargando…

Inhibition of SGLT2 alleviates diabetic nephropathy by suppressing high glucose‐induced oxidative stress in type 1 diabetic mice

It is unclear whether the improvement in diabetic nephropathy by sodium glucose cotransporter 2 (SGLT2) inhibitors is caused by a direct effect on SGLT2 or by the improvement in hyperglycemia. Here, we investigated the effect of dapagliflozin on early‐stage diabetic nephropathy using a mouse model o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hatanaka, Takashi, Ogawa, Daisuke, Tachibana, Hiromi, Eguchi, Jun, Inoue, Tatsuyuki, Yamada, Hiroshi, Takei, Kohji, Makino, Hirofumi, Wada, Jun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5242174/ https://www.ncbi.nlm.nih.gov/pubmed/28116093 http://dx.doi.org/10.1002/prp2.239

Ejemplares similares

Long-Term Treatment with the Sodium Glucose Cotransporter 2 Inhibitor, Dapagliflozin, Ameliorates Glucose Homeostasis and Diabetic Nephropathy in db/db Mice
por: Terami, Naoto, et al.
Publicado: (2014)

Urinary Fetuin-A Is a Novel Marker for Diabetic Nephropathy in Type 2 Diabetes Identified by Lectin Microarray
por: Inoue, Kentaro, et al.
Publicado: (2013)

Activation of Peroxisome Proliferator–Activated Receptor δ Inhibits Streptozotocin-Induced Diabetic Nephropathy Through Anti-Inflammatory Mechanisms in Mice
por: Matsushita, Yuichi, et al.
Publicado: (2011)

Pemt Deficiency Ameliorates Endoplasmic Reticulum Stress in Diabetic Nephropathy
por: Watanabe, Mayu, et al.
Publicado: (2014)

Nuclear Hormone Receptor Expression in Mouse Kidney and Renal Cell Lines
por: Ogawa, Daisuke, et al.
Publicado: (2014)

Urinary angiotensinogen is a marker for tubular injuries in patients with type 2 diabetes
por: Terami, Takahiro, et al.
Publicado: (2013)

Amelioration of diabetic nephropathy by SGLT2 inhibitors independent of its glucose-lowering effect: A possible role of SGLT2 in mesangial cells
por: Maki, Toshinobu, et al.
Publicado: (2019)

High Glucose Increases Metallothionein Expression in Renal Proximal Tubular Epithelial Cells
por: Ogawa, Daisuke, et al.
Publicado: (2011)

Microinflammation in the pathogenesis of diabetic nephropathy
por: Shikata, Kenichi, et al.
Publicado: (2013)

A new Classification of Diabetic Nephropathy 2014: a report from Joint Committee on Diabetic Nephropathy
por: Haneda, Masakazu, et al.
Publicado: (2015)

SGLT2 Inhibitors as a Therapeutic Option for Diabetic Nephropathy
por: Kawanami, Daiji, et al.
Publicado: (2017)

SGLT2 inhibition to address the unmet needs in diabetic nephropathy
por: Barutta, Federica, et al.
Publicado: (2019)

A SGLT2 Inhibitor Dapagliflozin Alleviates Diabetic Cardiomyopathy by Suppressing High Glucose-Induced Oxidative Stress in vivo and in vitro
por: Xing, Yu-jie, et al.
Publicado: (2021)

Underutilization of Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitors in Diabetic Nephropathy Patients in Government-Run Hospitals in India
por: Maradia, Jay, et al.
Publicado: (2023)

Combination therapy with an angiotensin‐converting‐enzyme inhibitor and an angiotensin II receptor antagonist ameliorates microinflammation and oxidative stress in patients with diabetic nephropathy
por: Nakamura, Akihiko, et al.
Publicado: (2012)

Antiangiogenic Therapy for Diabetic Nephropathy
por: Tanabe, Katsuyuki, et al.
Publicado: (2017)

Bilateral dystonia in type 1 diabetes: a case report
por: Yasuhara, Akihiro, et al.
Publicado: (2008)

Epigenetic regulation of core genes linking to diabetic nephropathy progression: Lesson from FinnDiane type 1 diabetes study
por: Makino, Hirofumi, et al.
Publicado: (2023)

Case of emphysematous cholecystitis in a patient with type 2 diabetes mellitus associated with schizophrenia
por: Ogawa, Ayu, et al.
Publicado: (2012)

264 Effective Reduction of Diabetic Nephropathy-Induced Albuminuria With SGLT2 inhibitor Monotherapy
Publicado: (2021)

Randomized trial of an intensified, multifactorial intervention in patients with advanced‐stage diabetic kidney disease: Diabetic Nephropathy Remission and Regression Team Trial in Japan (DNETT‐Japan)
por: Shikata, Kenichi, et al.
Publicado: (2020)

Effects of SGLT2 Inhibition in Human Kidney Proximal Tubular Cells—Renoprotection in Diabetic Nephropathy?
por: Panchapakesan, Usha, et al.
Publicado: (2013)

Hypoxia-inducible factor-1α is the therapeutic target of the SGLT2 inhibitor for diabetic nephropathy
por: Bessho, Ryoichi, et al.
Publicado: (2019)

Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease
por: Kurose, Yuko, et al.
Publicado: (2013)

SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels
por: Suga, Takayoshi, et al.
Publicado: (2018)

Taurine Alleviates the Progression of Diabetic Nephropathy in Type 2 Diabetic Rat Model
por: Koh, Jang Hyun, et al.
Publicado: (2014)

Overexpression of SGLT2 in the kidney of a P. gingivalis LPS-induced diabetic nephropathy mouse model
por: Kajiwara, Koichiro, et al.
Publicado: (2021)

Spironolactone alleviates diabetic nephropathy through promoting autophagy in podocytes
por: Dong, Dan, et al.
Publicado: (2019)

Carbon monoxide alleviates senescence in diabetic nephropathy by improving autophagy
por: Chen, Li, et al.
Publicado: (2021)

Melatonin alleviates renal injury by activating mitophagy in diabetic nephropathy
por: Tang, Hanfen, et al.
Publicado: (2022)

Paratubular basement membrane insudative lesions predict renal prognosis in patients with type 2 diabetes and biopsy-proven diabetic nephropathy
por: Mise, Koki, et al.
Publicado: (2017)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease
por: Aftab, Saba, et al.
Publicado: (2020)

PSUN199 SGLT2-Inhibitor Prescription Rates in Individuals with Diabetic Nephropathy at a Teaching Outpatient Clinic
por: Abdulwahid, Tiba, et al.
Publicado: (2022)

Acatalasemic mice are mildly susceptible to adriamycin nephropathy and exhibit increased albuminuria and glomerulosclerosis
por: Takiue, Keiichi, et al.
Publicado: (2012)

SGLT2 inhibition alleviated hyperglycemia, glucose intolerance, and dumping syndrome-like symptoms in a patient with glycogen storage disease type Ia: a case report
por: Katayama, Daisuke, et al.
Publicado: (2021)

Sodium glucose cotransporter (SGLT)-2 inhibitors alleviate the renal stress responsible for sympathetic activation
por: Sano, Motoaki
Publicado: (2020)

Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats
por: Ito, Daisuke, et al.
Publicado: (2015)

Non-diabetic urine glucose in idiopathic membranous nephropathy
por: Liu, Lingling, et al.
Publicado: (2022)

Combining SGLT2 Inhibition With a Thiazolidinedione Additively Attenuate the Very Early Phase of Diabetic Nephropathy Progression in Type 2 Diabetes Mellitus
por: Han, Eugene, et al.
Publicado: (2018)

Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors
por: Ogawa, Wataru, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fethqq7ut90l5bp494hmg27d8h